Donor-Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
24 01 2021
Historique:
received: 31 12 2020
accepted: 12 01 2021
entrez: 27 1 2021
pubmed: 28 1 2021
medline: 25 9 2021
Statut: epublish

Résumé

Patients with a variety of blood, immune, and metabolic disorders may require an allogeneic hematopoietic stem cell transplant as part of their treatment. However, over 70% of these patients do not have a matched sibling donor and require an alternative donor, such as a matched unrelated donor. We present a multi-part story of a Canadian stem cell recipient who underwent transplantation for treatment of refractory chronic myelogenous leukemia, and the matched unrelated donor who saved his life. The story segments feature excerpts from interviews with the donor and the recipient, along with representative images of both storytellers. The excerpts were optimized for publication on social media and were arranged to build a story arc that parallels the journey of the donor and recipient together. This donor-recipient story may serve as a resource to help raise awareness about stem cell donation and to encourage eligible individuals to register as donors. The story is one of several developed by Why We Swab, a library of stories in stem cell donation in Canada (Facebook, Twitter, and Instagram; @WhyWeSwab) to support the recruitment of committed unrelated donors.

Identifiants

pubmed: 33498807
pii: curroncol28010067
doi: 10.3390/curroncol28010067
pmc: PMC7924398
doi:

Types de publication

Case Reports Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

689-692

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Références

JAMA. 2001 Oct 17;286(15):1897-902
pubmed: 11597295
Health Promot Pract. 2009 Apr;10(2):186-91
pubmed: 19372280
Blood. 2016 Jan 14;127(2):260-7
pubmed: 26527675
Hematol Oncol Stem Cell Ther. 2020 Dec;13(4):220-231
pubmed: 32387075

Auteurs

Elena Kum (E)

Stem Cell Club, Toronto, ON M2H 3L2, Canada.
Faculty of Health Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada.

Gabriele Jagelaviciute (G)

Stem Cell Club, Toronto, ON M2H 3L2, Canada.
Faculty of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.

Edward Li (E)

Stem Cell Club, Toronto, ON M2H 3L2, Canada.
Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada.

Kenneth Williams (K)

Stem Cell Club, Toronto, ON M2H 3L2, Canada.
Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada.

Santhosh Thyagu (S)

Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada.
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.

Warren Fingrut (W)

Stem Cell Club, Toronto, ON M2H 3L2, Canada.
Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 298, New York, NY 10065, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH